Truist Securities Reiterates Hold Rating on Biogen (BIIB)
Tweet Send to a Friend
Truist Securities analyst Danielle Brill reiterated a Hold rating and $189.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "BIIB080 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


